{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:10:56Z","timestamp":1770898256640,"version":"3.50.1"},"reference-count":82,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,23]]},"DOI":"10.18632\/oncotarget.7005","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T07:42:07Z","timestamp":1453707727000},"page":"9271-9287","source":"Crossref","is-referenced-by-count":28,"title":["MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes"],"prefix":"10.18632","volume":"7","author":[{"given":"Aroa","family":"Soriano","sequence":"first","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Par\u00eds-Coderch","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Jubierre","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Tumor Angiogenesis Group, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institut de Neuroci\u00e8ncies and Departament de Bioqu\u00edmica i Biologia Molecular, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Piskareva","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Bray","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Vidal","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Almaz\u00e1n-Moga","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Molist","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Roma","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Bayascas","sequence":"additional","affiliation":[{"name":"Institut de Neuroci\u00e8ncies and Departament de Bioqu\u00edmica i Biologia Molecular, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Casanovas","sequence":"additional","affiliation":[{"name":"Tumor Angiogenesis Group, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond L.","family":"Stallings","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 S\u00e1nchez","family":"de Toledo","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad","family":"Gallego","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel F.","family":"Segura","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-UAB, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc3679","article-title":"The prenatal origins of cancer","volume":"14","author":"Weiss","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pcl.2014.09.015","article-title":"Neuroblastoma: paradigm for precision medicine","volume":"62","author":"Park","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcb.22094","article-title":"New therapeutic targets for the treatment of high-risk neuroblastoma","volume":"107","author":"Danks","year":"2009","journal-title":"J Cell Biochem"},{"key":"4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Reynolds","year":"1999","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Machin","year":"2008","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/pbc.21713","article-title":"Outcomes of the POG 9340\/9341\/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group","volume":"51","author":"Kretschmar","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"key":"8","first-page":"747","article-title":"How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture","volume":"53","author":"Gottesman","year":"1993","journal-title":"Cancer Res"},{"key":"9","first-page":"6462","article-title":"Resistance to chemotherapy mediated by TrkB in neuroblastomas","volume":"62","author":"Brodeur","year":"2002","journal-title":"Cancer Res"},{"key":"10","first-page":"6756","article-title":"Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3\u2032-kinase pathway","volume":"62","author":"Thiele","year":"2002","journal-title":"Cancer Res"},{"key":"11","first-page":"3737","article-title":"Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity","volume":"56","author":"Thiele","year":"1996","journal-title":"Cancer Res"},{"key":"12","first-page":"6185","article-title":"Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines","volume":"61","author":"Reynolds","year":"2001","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.1012351108","article-title":"RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma","volume":"108","author":"Mayes","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"14","doi-asserted-by":"crossref","first-page":"25549","DOI":"10.1074\/jbc.M314182200","article-title":"Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation","volume":"279","author":"Nakagawara","year":"2004","journal-title":"J Biol Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-10-1129","article-title":"Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma","volume":"17","author":"Fischer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"16","first-page":"1543","article-title":"Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification","volume":"143","author":"Nunez","year":"1993","journal-title":"Am J Pathol"},{"key":"17","first-page":"4315","article-title":"Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"60","author":"Gross","year":"2000","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1990.8.1.128","article-title":"Expression of the multidrug resistance, MDR1, gene in neuroblastomas","volume":"8","author":"Gottesman","year":"1990","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJM199601253340405","article-title":"Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma","volume":"334","author":"Haber","year":"1996","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1038\/emboj.2012.119","article-title":"Not lost in translation: stepwise regulation of microRNA targets","volume":"31","author":"Novina","year":"2012","journal-title":"Embo J"},{"key":"21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1517\/14728222.2010.510136","article-title":"Therapeutic targeting of miRNAs in neuroblastoma","volume":"14","author":"Bray","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"22","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1158\/0008-5472.CAN-10-0970","article-title":"microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1158\/0008-5472.CAN-05-4618","article-title":"Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number","volume":"66","author":"Okawa","year":"2006","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: determinants beyond seed pairing","volume":"27","author":"Bartel","year":"2007","journal-title":"Mol Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"Rajewsky","year":"2005","journal-title":"Nat Genet"},{"key":"26","first-page":"D149","article-title":"The microRNA. org resource: targets and expression","volume":"36","author":"Sander","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"27","first-page":"5396","article-title":"Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy","volume":"58","author":"Reynolds","year":"1998","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"37347","DOI":"10.1074\/jbc.M111.235531","article-title":"miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2","volume":"286","author":"Parmar","year":"2011","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-4598-12-23","article-title":"MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1","volume":"12","author":"Stallings","year":"2013","journal-title":"Mol Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"Lukas","year":"2007","journal-title":"Oncogene"},{"key":"31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2005.01.048","article-title":"Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma","volume":"228","author":"Hogarty","year":"2005","journal-title":"Cancer Lett"},{"key":"32","first-page":"8","article-title":"Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line","volume":"61","author":"Lunec","year":"2001","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/0008-5472.CAN-05-2623","article-title":"Increased frequency of aberrations in the p53\/MDM2\/p14(ARF) pathway in neuroblastoma cell lines established at relapse","volume":"66","author":"Tweddle","year":"2006","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"10351","DOI":"10.1158\/0008-5472.CAN-06-4345","article-title":"p53 determines multidrug sensitivity of childhood neuroblastoma","volume":"67","author":"Gudkov","year":"2007","journal-title":"Cancer Res"},{"key":"35","first-page":"4711","article-title":"Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance","volume":"55","author":"Israel","year":"1995","journal-title":"Cancer Res"},{"key":"36","first-page":"2576","article-title":"Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis","volume":"55","author":"Castle","year":"1995","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ijc.25842","article-title":"Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma","volume":"129","author":"Cheung","year":"2011","journal-title":"Int J Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/modpathol.2008.135","article-title":"Potentially important microRNA cluster on chromosome 17p13. 1 in primary peritoneal carcinoma","volume":"22","author":"Aziz","year":"2009","journal-title":"Mod Pathol"},{"key":"39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/ERC-11-0082","article-title":"The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma","volume":"18","author":"Lui","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.7314\/APJCP.2013.14.6.3499","article-title":"MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells","volume":"14","author":"Wang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"41","doi-asserted-by":"crossref","first-page":"e60155","DOI":"10.1371\/journal.pone.0060155","article-title":"The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma","volume":"8","author":"Inazawa","year":"2013","journal-title":"PLoS One"},{"key":"42","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12032-014-0844-4","article-title":"Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma","volume":"31","author":"Wang","year":"2014","journal-title":"Med Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ijc.27657","article-title":"Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas","volume":"132","author":"Zen","year":"2013","journal-title":"Int J Cancer"},{"key":"44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12032-010-9797-4","article-title":"miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2","volume":"29","author":"Liu","year":"2012","journal-title":"Med Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2014.05.011","article-title":"The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E","volume":"449","author":"Ma","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.surg.2012.12.004","article-title":"MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor","volume":"153","author":"Wang","year":"2013","journal-title":"Surgery"},{"key":"47","doi-asserted-by":"crossref","first-page":"e84311","DOI":"10.1371\/journal.pone.0084311","article-title":"The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195\/497 cluster","volume":"9","author":"Enokida","year":"2014","journal-title":"PLoS One"},{"key":"48","doi-asserted-by":"crossref","first-page":"e92847","DOI":"10.1371\/journal.pone.0092847","article-title":"Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbrc.2014.05.053","article-title":"MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1","volume":"449","author":"Shi","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"50","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/onc.2012.214","article-title":"MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer","volume":"32","author":"Zhang","year":"2013","journal-title":"Oncogene"},{"key":"51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbrc.2013.05.010","article-title":"Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer","volume":"435","author":"Chen","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2407-10-109","article-title":"Identification of differentially expressed microRNAs in human male breast cancer","volume":"10","author":"Langer","year":"2010","journal-title":"BMC Cancer"},{"key":"53","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/1078-0432.CCR-10-1800","article-title":"Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer","volume":"17","author":"Zeng","year":"2011","journal-title":"Clin Cancer Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3892\/etm.2011.428","article-title":"miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w","volume":"3","author":"Fang","year":"2012","journal-title":"Exp Ther Med"},{"key":"55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1475-2867-13-95","article-title":"MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer","volume":"13","author":"Fang","year":"2013","journal-title":"Cancer Cell Int"},{"key":"56","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1746-1596-8-172","article-title":"Expression of microRNA-497 and its prognostic significance in human breast cancer","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn Pathol"},{"key":"57","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s13277-013-1342-6","article-title":"MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis","volume":"35","author":"Yin","year":"2014","journal-title":"Tumour Biol"},{"key":"58","doi-asserted-by":"publisher","first-page":"26457","DOI":"10.18632\/oncotarget.4762","article-title":"MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR\/P70S6K1","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"59","first-page":"776","article-title":"Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma","volume":"73","author":"Cole","year":"2012","journal-title":"Cancer Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-06-2201","article-title":"Activation of Akt predicts poor outcome in neuroblastoma","volume":"67","author":"Fulda","year":"2007","journal-title":"Cancer Res"},{"key":"61","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Cantley","year":"2007","journal-title":"Cell"},{"key":"62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbior.2014.04.001","article-title":"Signaling specificity in the Akt pathway in biology and disease","volume":"55","author":"Marmiroli","year":"2014","journal-title":"Adv Biol Regul"},{"key":"63","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma","volume":"64","author":"Robertson","year":"2004","journal-title":"Cancer Res"},{"key":"64","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1073\/pnas.1414573112","article-title":"Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression","volume":"112","author":"Fuller","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"65","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ijc.26010","article-title":"Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells","volume":"130","author":"Muise-Helmericks","year":"2012","journal-title":"Int J Cancer"},{"key":"66","first-page":"211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Gavard","year":"2013","journal-title":"Front Oncol"},{"key":"67","first-page":"1900","article-title":"High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas","volume":"6","author":"Himelstein","year":"2000","journal-title":"Clin Cancer Res"},{"key":"68","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","article-title":"The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts","volume":"60","author":"Azarbayjani","year":"2006","journal-title":"Pediatr Res"},{"key":"69","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Davidoff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"70","unstructured":"Mirna Therapeutics, Inc. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. ClinicalTrials.gov. Bethesda (MD), National Library of Medicine (US). 2000-[cited 2015 Dec 16]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01829971. NLM identifier: NCT01829971."},{"key":"71","doi-asserted-by":"publisher","first-page":"872","DOI":"10.18632\/oncotarget.1825","article-title":"miR-34: from bench to bedside","volume":"5","author":"Knight","year":"2014","journal-title":"Oncotarget"},{"key":"72","unstructured":"University of Sidney. MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy. ClinicalTrials.gov. Bethesda (MD), National Library of Medicine (US). 2000-[cited 2015 Dec 16]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02369198. NLM identifier: NCT02369198."},{"key":"73","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.3390\/ijms160818077","article-title":"miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients","volume":"16","author":"Deutsch","year":"2015","journal-title":"Int J Mol Sci"},{"key":"74","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1038\/onc.2012.311","article-title":"Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs","volume":"32","author":"van Sluis","year":"2013","journal-title":"Oncogene"},{"key":"75","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ijc.28091","article-title":"MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A","volume":"133","author":"Sprussel","year":"2013","journal-title":"Int J Cancer"},{"key":"76","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ng.2436","article-title":"LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression","volume":"44","author":"Volckmann","year":"2012","journal-title":"Nat Genet"},{"key":"77","doi-asserted-by":"crossref","first-page":"e7850","DOI":"10.1371\/journal.pone.0007850","article-title":"Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival","volume":"4","author":"Higgins","year":"2009","journal-title":"PLoS One"},{"key":"78","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/onc.2009.429","article-title":"MYCN\/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN\/c-MYC-activated tumors","volume":"29","author":"Schramm","year":"2010","journal-title":"Oncogene"},{"key":"79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Trono","year":"1996","journal-title":"Science"},{"key":"80","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficientgene delivery","volume":"72","author":"Trono","year":"1998","journal-title":"J Virol"},{"key":"81","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212\u0394\u0394C(T)) Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"82","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.molcel.2009.08.020","article-title":"miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to \u201cseedless\u201d 3\u2032UTR microRNA recognition elements","volume":"35","author":"Hide","year":"2009","journal-title":"Mol Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:51:58Z","timestamp":1589219518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,2,23]]}},"alternative-id":["7005","26824183"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7005","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]}}}